Natixis Advisors, L.P. Spring Works Therapeutics, Inc. Transaction History

Natixis Advisors, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$18.36 - $60.07 $254,377 - $832,269	-13,855 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$48.97 - $65.46 $195 - $261	-4 Reduced 0.03%	13,855 $782,000
Q4 2021 Feb 08, 2022	SELL	$53.3 - $75.84 $40,294 - $57,335	-756 Reduced 5.17%	13,859 $859,000
Q3 2021 Nov 15, 2021	BUY	$62.66 - $88.26 $3,696 - $5,207	59 Added 0.41%	14,615 $927,000
Q2 2021 Aug 12, 2021	BUY	$67.45 - $85.63 $162,149 - $205,854	2,404 Added 19.78%	14,556 $1.2 Million
Q1 2021 May 05, 2021	BUY	$65.1 - $93.59 $791,095 - $1.14 Million	12,152 New	12,152 $894,000

237

68.9M

144K

257K

Ticker SWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,401,100
Market Cap $2.25B
Description
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...

Get notified when there are updates to the investment portfolio of Natixis Advisors, L.P., based on Form 13F filings with the SEC.

Stay updated on Natixis Advisors, L.P. with notifications on news.